Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer
Status:
Terminated
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well real-time pharmacokinetic therapeutic drug monitoring
works in preventing stomatitis from developing in patients with hormone receptor positive
breast cancer, pancreatic neuroendocrine tumors, or kidney cancer that are receiving a type
of cancer drug called everolimus. Stomatitis is a common side effect of everolimus that
causes inflammation of the mouth, with or without oral ulcers, and frequently leads to
patients discontinuing the medication. Monitoring the blood levels of everolimus and making
adjustments in a patient's dose may be able to decrease the incidence of stomatitis, while
maintaining the effectiveness of everolimus to treat the cancer.